Traditional cancer therapeutics, such as chemotherapies, are often limited by their non-
specific nature, causing harm to non-malignant tissues. Over the past several decades …

Tumor immunotherapy is only effective in a fraction of patients due to a low response rate
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …

Hydrogel is a type of versatile platform with various biomedical applications after rational
structure and functional design that leverages on material engineering to modulate its …

Glioblastoma multiforme (GBM) remains incurable despite aggressive implementation of
multimodal treatments after surgical debulking. Almost all patients with GBM relapse within a …

Nanomedicine holds promise to enhance cancer immunotherapy; however, its potential to
elicit highly specific anti-tumor immunity without compromising immune tolerance has yet to …

Effective drug delivery and prevention of postoperative recurrence are significant challenges
for current glioblastoma (GBM) treatment. Poor drug delivery is mainly due to the presence …

Immunosuppressive cells residing in the tumor microenvironment, especially tumor
associated macrophages (TAMs), hinder the infiltration and activation of T cells, limiting the …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few
treatment options. Here, building on the observation of elevated lactate (LA) in resected …

The major challenges of immunotherapy for glioblastoma are that drugs cannot target tumor
sites accurately and properly activate complex immune responses. Herein, we design and …

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …